TuHURA Biosciences and Kintara Therapeutics Complete Merger

TuHURA Biosciences, Inc. has finalized its merger with Kintara Therapeutics, Inc., subsequently operating as TuHURA Biosciences. The company focuses on advancing technologies to counteract resistance in cancer immunotherapy. The lead program, aimed at Merkel Cell carcinoma, is set to enter a Phase 3 trial in early 2025 under an FDA Special Protocol Assessment agreement.

With $31 million in funding from the merger, the combined operations are projected to be financed until late 2025. Shares will trade under "HURA" on Nasdaq starting October 18, 2024. Post-merger, Kintara and TuHURA equityholders own 2.85% and 97.15% respectively, potentially adjusting under milestone achievements.

CEO James Bianco highlights the merger's significance in addressing current cancer immunotherapy challenges. Key focuses include the development of IFx-2.0 and tumor microenvironment modulators, leveraging proprietary technologies to prevent treatment resistance.